Details:
Under the licence agreement, Bristol Myers Squibb has selected an undisclosed number of programmes that were rapidly developed and progressed using Evotec's precision medicine platforms for further development within the expanded collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $4,000.0 million Upfront Cash: $50.0 million
Deal Type: Expanded Collaboration July 11, 2023
Details:
Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: SciNeuro Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2023
Details:
EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications. The EVT8683 programme originates from a phenotypic screen conducted by Evotec using its IPSC drug discovery platform.
Lead Product(s): EVT8683
Therapeutic Area: Neurology Product Name: EVT8683
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 16, 2022
Details:
The initial agreement, which granted Pfizer access to data of interest from CENTOGENE’s Bio/Databank, was established in 2019 to advance the discovery and validation of novel genetic targets as candidates for the development of new therapies for rare diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 17, 2022
Details:
The collaboration will incorporate DZNE’s expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 17, 2021